FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP‐activated protein kinase–Caspase 6 signal axis

Lintao Song, Luyao Wang, Yushu Hou, Jie Zhou, Chuchu Chen, Xianxi Ye, Wenliya Dong, Huan Gao, Yi Liu, Guanting Qiao, Tongtong Pan, Qiong Chen, Yu Cao, Fengjiao Hu, Zhiheng Rao, Yajing Chen, Yu Han, Minghua Zheng, Yongde Luo, Xiaokun Li, Yongping Chen, Zhifeng Huang – 11 February 2022

Effect of Omega‐3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD

Václav Šmíd, Karel Dvořák, Petr Šedivý, Vít Kosek, Martin Leníček, Monika Dezortová, Jana Hajšlová, Milan Hájek, Libor Vítek, Kamila Bechyňská, Radan Brůha – 10 February 2022 – Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. n‐3 polyunsaturated fatty acids (n‐3‐PUFAs) have been reported to ameliorate the progression of NAFLD in experimental studies; however, clinical trials have yielded contradictory results.

Advanced Liver Fibrosis Correlates With Impaired Efficacy of Pfizer‐BioNTech COVID‐19 Vaccine in Medical Employees

Asher Shafrir, Johnny Amer, David Hakimian, Yael Milgrom, Muhammad Massarwa, Wadi Hazou, Ashraf Imam, Abed Khalaileh, Rifaat Safadi – 10 February 2022 – The Pfizer‐BioNTech coronavirus disease 2019 (COVID‐19) vaccine has been offered to nonallergic ≥16‐year‐old Israeli adults since December 19, 2020. Data regarding factors associated with vaccine ineffectiveness are limited. The aim of this study is to assess the impact of hepatic fibrosis on the efficacy of the BioNTech vaccine.

A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease

Grazia Pennisi, Rosaria Maria Pipitone, Marco Enea, Antonio De Vincentis, Salvatore Battaglia, Vito Di Marco, Vincenzo Di Martino, Federica Spatola, Federica Tavaglione, Umberto Vespasiani‐Gentilucci, Rossella Zito, Stefano Romeo, Calogero Cammà, Antonio Craxì, Stefania Grimaudo, Salvatore Petta – 10 February 2022 – Nonalcoholic fatty liver disease (NAFLD) is an emerging cause of liver‐related events (LREs). Here, we have assessed the ability of a composite score based on clinical features, metabolic comorbidities, and genetic variants to predict LREs.

Complete transition from open surgery to laparoscopy: 8‐year experience with more than 500 laparoscopic living donor hepatectomies

Jinsoo Rhu, Gyu‐Seong Choi, Jong Man Kim, Choon Hyuck David Kwon, Jae‐Won Joh – 8 February 2022 – This study was designed to review laparoscopic living donor liver transplantations (LDLTs) at a single center that achieved complete transition from open surgery to laparoscopy. LDLTs performed from January 2013 to July 2021 were reviewed. Comparisons between open and laparoscopic surgeries were performed according to periods divided into initial, transition, and complete transition periods. A total of 775 LDLTs, 506 laparoscopic and 269 open cases, were performed.

Subscribe to